R&D PIPELINE THERAPY AREAS

R&D Pipeline Therapy Areas

The agents and uses mentioned below are investigational and have not been approved by the US Food and Drug Administration (FDA) for the uses under investigation. No conclusions regarding safety and efficacy should be drawn for such agents and uses.
Sanofi’s oncology pipeline strategy is to leverage new technologies empowering molecular oncology, immune-oncology, and genomic medicine platforms with a focus on multiple myeloma (MM) and other blood cancers, as well as solid tumors.

Latest News from Sanofi

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

Educational Resources

General

Pre-approval Information Exchange: Overview of the Sanofi Specialty Care Pipeline
A presentation providing a brief general overview of Sanofi’s specialty care R&D pipeline, including investigational agents and proposed mechanistic targets in Multiple Myeloma. All information is updated quarterly.